Degarelix

Brand names: Firmagon · Active ingredient: Degarelix

In short: FIRMAGON® is indicated for treatment of patients with advanced prostate cancer.

Forms & strengthsFor injection: FIRMAGON (240 mg): Two single-dose vials each delivering 120 mg of degarelix in a white to off-white lyophilized powder for reconstitution supplied with diluent in two prefilled syringes. …
LabelFerring Pharmaceuticals Inc.
Label updatedFeb 01, 2024

What is Degarelix used for?

FIRMAGON® is indicated for treatment of patients with advanced prostate cancer.

Degarelix dosage

FIRMAGON is administered as a subcutaneous injection in the abdominal region only at the dosages in Table 1 below.

Starting Dosage | Maintenance Dosage – Administered once every 28 days

240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mL | The first maintenance dose should be given 28 days after the starting dose.

80 mg given as one subcutaneous injection at a concentration of 20 mg/mL

FIRMAGON is to be administered by a healthcare professional only.

Before administering FIRMAGON read the Instructions for reconstitution and administration carefully.

As with other drugs administered by subcutaneous injection, the injection site should vary periodically. Injections should be given only in areas of the abdomen that will not be exposed to pressure, e.g., not close to waistband or belt nor close to the ribs.

FIRMAGON is supplied as a powder to be reconstituted with Sterile Water for Injection, USP.

Starting dose (240 mg): Two single-dose vials each delivering 120 mg of degarelix in a white to off-white lyophilized powder for reconstitution supplied with diluent in two prefilled syringes. Each vial is to be reconstituted with a prefilled syringe containing 3 mL of Sterile Water for Injection. 3 mL is withdrawn to deliver 120 mg degarelix at a concentration of 40 mg/mL.

Maintenance dose (80 mg): One single-dose vial delivering 80 mg of degarelix in a white to off-white lyophilized powder for reconstitution supplied with diluent in one prefilled syringe. Each vial is to be reconstituted with a prefilled syringe containing 4.2 mL of Sterile Water for Injection. 4 mL is withdrawn to deliver 80 mg degarelix at a concentration of 20 mg/mL.

Follow the instructions for reconstitution closely and read the complete instructions before performing the subcutaneous injection.

Reconstituted drug must be administered within one hour after addition of Sterile Water for Injection, USP.

Do not shake the vials.

Follow aseptic technique.

FIRMAGON 240 mg Starting Dose Kit contains:

2 vials containing the 120 mg FIRMAGON powder (a)

2 syringes containing Sterile Water for Injection, USP (b)

2 vial adapters (c)

2 25 gauge × 1 inch injection needles (d)

2 plunger rods (e)

FIRMAGON 80 mg Maintenance Dose Kit contains:

1 vial containing the 80 mg FIRMAGON powder (f)

1 syringe containing Sterile Water for Injection, USP (g)

1 vial adapter (h)

1 25 gauge × 1 inch injection needle (i)

1 plunger rod (j)

In addition the healthcare professional will need:

gloves (k)

alcohol pads (l)

a clean, flat surface (m) to work on, like a table

a sharps disposal container (n) for throwing away your used needles and syringes. See "Disposing used needles and syringes" at the end of these instructions. …

How to take Degarelix — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Hypersensitivity

Inform patients that if they have experienced severe hypersensitivity with degarelix or to any of the product components, FIRMAGON is contraindicated . Instruct patients to immediately report signs of a severe hypersensitivity reaction .

QT Interval Prolongation

Advise patients that androgen deprivation therapy treatment with FIRMAGON may prolong the QT interval. Inform patients of the signs and symptoms of QT prolongation. Advise patients to contact their healthcare provider immediately for signs or symptoms of QT prolongation .

Androgen Deprivation

Inform patients about adverese reactions related to androgen deprivation therapy with FIRMAGON, including hot flashes, flushing of the skin, increased weight, decreased sex drive, and difficulties with erectile function .

Injection Site Reactions

Inform patients that FIRMAGON may cause redness, swelling, and itching at the injection site. Advise patients that these adverse reactions are usually mild, self limiting, and decrease within three days .

Infertility

Inform patients that FIRMAGON may cause infertility .

Warnings & precautions

Do not take this medicine if: FIRMAGON is contraindicated in patients with history of severe hypersensitivity to degarelix or to any of the product components .

FIRMAGON is contraindicated in patients with history of severe hypersensitivity to degarelix or to any of the product components .

Hypersensitivity reactions, including anaphylaxis, urticaria and angioedema, have been reported post-marketing with FIRMAGON.

In case of a severe hypersensitivity reaction, discontinue FIRMAGON immediately if the injection has not been completed, and manage as clinically indicated. Patients with a known history of severe hypersensitivity reactions to FIRMAGON should not be re-challenged with FIRMAGON.

Androgen deprivation therapy may prolong the QT interval. Providers should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, frequent electrolyte abnormalities, and in patients taking drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected. Consider periodic monitoring of electrocardiograms and electrolytes.

In the randomized, active-controlled trial comparing FIRMAGON to leuprolide, periodic electro-cardiograms were performed. Seven patients, three (<1%) in the pooled degarelix group and four (2%) patients in the leuprolide 7.5 mg group, had a QTcF ≥ 500 msec. From baseline to end of study, the median change for FIRMAGON was 12.3 msec and for leuprolide was 16.7 msec.

FIRMAGON results in suppression of the pituitary gonadal system. Results of diagnostic tests of the pituitary gonadotropic and gonadal functions conducted during and after FIRMAGON may be affected. The therapeutic effect of FIRMAGON should be monitored by measuring serum concentrations of prostate-specific antigen (PSA) periodically. …

Degarelix side effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

FIRMAGON was studied in a randomized, open-label trial in which patients with prostate cancer were randomized to receive FIRMAGON (subcutaneous) or leuprolide (intramuscular) monthly for 12 months .

The most common adverse reactions (≥10%) during FIRMAGON therapy are injection site reactions (e.g., pain, erythema, swelling or induration), hot flashes, and increases in serum levels of transaminases and gamma-glutamyltransferase (GGT). The majority of the adverse reactions were Grade 1 or 2, with Grade 3/4 adverse reaction incidences of 1% or less.

Adverse reactions reported in ≥ 5% of patients treated with FIRMAGON (subcutaneous) 240 mg starting dose and then 80 mg maintenance dose once every 28 days or who were treated with 7.5 mg of leuprolide (intramuscular) every 28 days are shown in Table 2.

FIRMAGON 240/80 mg (subcutaneous) N = 207 | Leuprolide 7.5 mg (intramuscular) N = 201

Any adverse reaction | 79% | 78%

Body as a whole

Injection site reactionsIncludes pain, erythema, swelling, induration, or nodule. …

Drug interactions

No drug-drug interaction studies were conducted.

Degarelix is not a substrate for the human CYP450 system. Degarelix is not an inducer or inhibitor of the CYP450 system in vitro. Therefore, clinically significant CYP450 pharmacokinetic drug-drug interactions are unlikely.

About this medicine

FIRMAGON is a sterile lyophilized powder for injection containing degarelix (as the acetate) and mannitol. Degarelix is a synthetic linear decapeptide amide containing seven unnatural amino acids, five of which are D-amino acids. The acetate salt of degarelix is a white to off-white amorphous powder of low density as obtained after lyophilization.

The chemical name of degarelix is D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-4-[[[(4S)-hexahydro-2,6-dioxo-4-pyrimidinyl]carbonyl]amino]-L phenylalanyl-4-[(aminocarbonyl)amino]-D-phenylalanyl-L-leucyl-N6–(1-methylethyl)-L-lysyl-L-prolyl. It has an empirical formula of C82H103N18O16Cl and a molecular weight of 1632.3 Da.

Degarelix acetate has the following structural formula:

FIRMAGON is available in two packaging configurations:

Starting Dose: Two vial carton with each vial delivering 120 mg of degarelix (equivalent to the median value of 126 mg degarelix acetate). Each 120 mg dose contains 150 mg mannitol. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID ab11dd8a-0fd9-4013-89ab-e114557c7e4b. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate